More tools:Markets·Screener·Research Chat

Alnylam Pharmaceuticals, Inc. (ALNY) Financial Statements

Alnylam Pharmaceuticals, Inc.
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001S7FTC8
XNAS · usd
281.26▼ 6.80 (-2.36%)
As of 2026-07-14
Valuation
Market Cap
Enterprise Value—
Trailing P/E
Price / Sales
EV / Revenue—
EV / EBITDA—
Financial Highlights
Revenue (TTM)$3.7B
Net Income (TTM)$313.7M
EBITDA
Diluted EPS (TTM)
EBITDA Margin15.0%
Net Debt—
Trading Information
Previous Close288.06
Day's Range279.43 – 286.76
52-Week Range273.11 – 495.55
Volume1.08M
Avg Volume1.44M
Share Statistics
Shares Outstanding133.5M
Employees2,500
ExchangeXNAS
Listed2004-05-28

Key questions about Alnylam Pharmaceuticals, Inc. (ALNY)

What is Alnylam Pharmaceuticals, Inc.'s Market Cap?
Alnylam Pharmaceuticals, Inc.'s Market Cap is $37.6B, based on as-reported figures from SEC (XBRL) filings.
What is Alnylam Pharmaceuticals, Inc.'s Trailing P/E?
Alnylam Pharmaceuticals, Inc.'s Trailing P/E is 119.7×, based on as-reported figures from SEC (XBRL) filings.
What is Alnylam Pharmaceuticals, Inc.'s Price / Sales?
Alnylam Pharmaceuticals, Inc.'s Price / Sales is 10.1×, based on as-reported figures from SEC (XBRL) filings.
What is Alnylam Pharmaceuticals, Inc.'s Revenue (TTM)?
Alnylam Pharmaceuticals, Inc.'s Revenue (TTM) is $3.7B, based on as-reported figures from SEC (XBRL) filings.
What is Alnylam Pharmaceuticals, Inc.'s Net Income (TTM)?
Alnylam Pharmaceuticals, Inc.'s Net Income (TTM) is $313.7M, based on as-reported figures from SEC (XBRL) filings.
What is Alnylam Pharmaceuticals, Inc.'s EBITDA?
Alnylam Pharmaceuticals, Inc.'s EBITDA is $556.4M, based on as-reported figures from SEC (XBRL) filings.
What is Alnylam Pharmaceuticals, Inc.'s Diluted EPS (TTM)?
Alnylam Pharmaceuticals, Inc.'s Diluted EPS (TTM) is 2.35, based on as-reported figures from SEC (XBRL) filings.
What is Alnylam Pharmaceuticals, Inc.'s EBITDA Margin?
Alnylam Pharmaceuticals, Inc.'s EBITDA Margin is 15.0%, based on as-reported figures from SEC (XBRL) filings.
Loading Income Statement…
Showing the most recent year. Subscribe for full statement history.
Income Statement(in millions of USD, except per-share data)
Source: Akyla.ai
Line ItemMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022Jun 30, 2022
Revenues:
Net product revenues
Net revenues from collaborations
Royalty revenue
Total revenues
YoY growth+96.4%+84.9%+149.3%+17.3%
Operating costs and expenses:
Cost of goods sold
Cost of collaborations and royalties
Research and development
Selling, general and administrative
Total operating costs and expenses
% of revenue77.0%88.0%70.5%102.1%
Income (loss) from operations
% of revenue23.0%12.0%29.5%-2.1%
Other (expense) income:
Interest expense
Interest income
Other (expense) income, net
Total other expense, net
Income (loss) before income taxes
Income tax expense (benefit)
Net income (loss)
% of revenue17.6%17.0%20.1%-8.6%
Net income (loss) per common share — basic
Net income (loss) per common share — diluted
Weighted-average common shares — basic
Weighted-average common shares — diluted—
Other comprehensive loss:
Unrealized (losses) gains on marketable securities
Foreign currency translation losses
Defined benefit pension plans, net of tax
Total other comprehensive loss
Comprehensive income (loss)